Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the ...

Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

Eli Lilly (LLY) is one of the stocks most watched ... Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

Eli Lilly (NYSE: LLY) has been a growth beast over the years and is now easily the most valuable healthcare company in the ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...